Radiodermatitis Market to Eyewitness Stunning Growth by 2027 Covid-19 Analysis

Posted by Sanyukta K on July 13th, 2022

Asia-Pacific is estimated to dominate the market throughout the analysis period, owing to the rise in disposable income, increase in expenditure on healthcare, rise in prevalence of cancer patients, and growth in adoption of advanced healthcare products. However, North America is expected to register highest CAGR during the forecast period, owing to inclusion of radiodermatitis products in reimbursement healthcare policy, rise in number of cancer patients, surge in demand for radiation therapy, and high expenditure in the healthcare sector.

Explore More Insights@ https://www.alliedmarketresearch.com/request-sample/4498

The high cost associated with radiodermatitis treatment is expected to curb market growth. In contrast, the increase in demand for reducing the side effects associated with radiation therapy is expected to provide beneficial opportunities for market expansion over the forecast period. Key factors contributing to the growth of the market include the spread of cancer and the increasing adoption of radiotherapy for treatment globally. In addition, the increase in geriatric population further fuels the growth of the radiodermatitis market.

This pandemic has disrupted growth in many economies across various domains. During the COVID-19 pandemic, leading cancer institutions reported that radiotherapy has proved to be the most appropriate and safe treatment option. Whereas, radiation dermatitis is a common side effect of radiotherapy, which can damage skin cells as it fights cancer cells. Hence, demand for radiodermatitis products is anticipated to increase simultaneously, which further boosts growth of the market.

Radiodermatitis, also known as radiation dermatitis, is a rare condition caused by radiation therapy for cancer and non-cancer care and has a major negative effect on physical health and quality of life of a patient. In addition, about half of patients undergoing cancer treatment have received radiation therapy during the disease and experienced a degree of skin reaction in almost all of them.

The development and severity of radiodermatitis is related to a number of treatment factors such as the total radiation dose, duration of radiotherapy, and treatment with chemotherapy. Furthermore, radiodermatitis can be classified as acute and chronic.

Key Market Players

• The 3m Company
• Bayer Ag.
• Bausch Health Companies Inc.
• Bmg Pharma S.P.A.
• Convatec Group Plc.
• Glaxosmithkline Plc
• Helsinn Healthcare Sa
• Molnlycke Health Care Ab
• Mylan N.V.
• Stratpharma Ag
• Smith & Nephew Plc

According to a new report published by Allied Market Research, titled, “Radiodermatitis Market by product, distribution channel, and region: Opportunity Analysis and Industry Forecast, 2019-2027,” The global radiodermatitis market size was valued at 7.48 million in 2019, and is projected to reach 9.68 million by 2027, registering a CAGR of 4.1% from 2020 to 2027.

Radiodermatitis, also known as radiation dermatitis, is a rare condition caused by radiation therapy for cancer and non-cancer care and has a major negative effect on physical health and quality of life of a patient. In addition, about half of patients undergoing cancer treatment have received radiation therapy during the disease and experienced a degree of skin reaction in almost all of them.

Key Advantages:

• By product, the topical segment accounted for the largest radiodermatitis market share in 2019.
• By on distribution channel, online pharmacy segment is expected to grow at the highest CAGR during the forecast period
• Asia-Pacific held the major share of the radiodermatitis market at CAGR of 3.3%.
• U.S. accounted for one-fifth share of the global radiodermatitis market in 2019.